Production (Stage)
FibroBiologics, Inc.
FBLG
$0.8087
-$0.0638-7.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 41.30% | 68.11% | 77.19% | 141.55% | -250.31% |
| Total Depreciation and Amortization | 17.52% | 17.69% | 27.68% | 41.41% | 42.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.10% | -98.02% | -604.58% | -782.77% | 683.80% |
| Change in Net Operating Assets | -471.12% | -187.74% | -108.73% | 752.11% | 262.40% |
| Cash from Operations | -23.39% | -91.94% | -128.80% | -19.82% | -109.97% |
| Capital Expenditure | -437.50% | -4,850.00% | 97.34% | -175.00% | 85.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -437.50% | -4,850.00% | 97.34% | -175.00% | 85.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 375.64% | 89.96% | -77.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -429.15% | 484.15% | 402.94% | 35.01% | -108.06% |